• Publications
  • Influence
Application of Patient-Reported Outcomes Measurement Information System to chronic pelvic pain.
STUDY OBJECTIVES To apply the Patient-Reported Outcomes Measurement Information System (PROMIS) recently developed by the National Institutes of Health in patients with chronic pelvic pain. SecondaryExpand
Dextroamphetamine sulfate, a very effective drug for pelvic pain relieved severe retroorbital stabbing pain in a woman with keratoconus who failed to respond to bilateral corneal implants.
PURPOSE To determine if dextroamphetamine sulfate therapy could relieve severe headaches related to keratoconus of the eyes. MATERIALS AND METHODS Dextroamphetamine sulfate 20 mg daily wasExpand
In vitro fertilization (IVF) outcome in women in overt menopause attempting to induce follicular maturation by follicle stimulating hormone (FSH) receptor down-regulation.
PURPOSE To determine the frequency of ovulation induction, obtaining oocytes leading to embryos, and pregnancy rates per embryo transfer in women with premature menopause. MATERIALS AND METHODSExpand
The use of granulocyte colony stimulating factor to enhance oocyte release in women with the luteinized unruptured follicle syndrome.
PURPOSE To determine if an injection of granulocyte colony stimulating factor (G-CSF) prevoulatory can enable oocyte release from the follicle in women who have failed to release in natural cyclesExpand
Serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF) which is found in high levels during pregnancy is not higher in women with progesterone (P) receptor (R)
PURPOSE To determine if serum levels of the immunomodulatory protein, the progesterone induced blocking factor (PIBF), which is present in high levels during normal pregnancy, is present in higherExpand
The progesterone receptor antagonist mifepristone does not lower serum progesterone induced blocking factor (PIBF) in the presence of progesterone.
PURPOSE To determine if mifepristone can lower serum levels of a progesterone (P) induced immunomodulatory protein believed to be needed for the fetus to escape immune surveillance. MATERIALS ANDExpand
Abstract 1282: Comparison of serum progesterone levels of the immunomodulatory protein, the progesterone induced blocking factor, in people with BRCA-2 mutations associated with and not associated
The BRCA genes normally provide proteins important in degradating the progesterone (P) receptor. BRCA1 and 2 mutations may make mutated protein, leading to prolongation of P receptor activity whichExpand
...
1
2
...